Innorna
1 known investors
Innorna develops mRNA-based therapeutics built on a proprietary platform featuring a lipid library of over 100,000 ionizable lipid structures and targeted LNP delivery systems. The company's pipeline spans vaccines, protein replacement therapies for chronic metabolic diseases, and in vivo immunotherapies for autoimmune conditions, with four candidates in clinical trials.
Investors · 1
Funding
SEC filings, press & company announcements- Undisclosed amountSeries BApr 2022Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Innorna do?
- Innorna develops mRNA-based therapeutics built on a proprietary platform featuring a lipid library of over 100,000 ionizable lipid structures and targeted LNP delivery systems. The company's pipeline spans vaccines, protein replacement therapies for chronic metabolic diseases, and in vivo immunotherapies for autoimmune conditions, with four candidates in clinical trials.
- Who are Innorna's investors?
- Innorna's investors include Blue Ocean Capital Group.